• Molecular NameRisperidone
  • Synonymrisperdone; Risperidona [Spanish]; risperidone; Risperidonum [Latin]
  • Weight410.493
  • Drugbank_IDDB00734
  • ACS_NO106266-06-2
  • Show 2D model
  • LogP (experiment)3.04
  • LogP (predicted, AB/LogP v2.0)2.97
  • pka3.11, 8.24
  • LogD (pH=7, predicted)1.76
  • Solubility (experiment)0.0666 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-3.53
  • LogSw (predicted, AB/LogsW2.0)0.1
  • Sw (mg/ml) (predicted, ACD/Labs)0.01
  • No.of HBond Donors0
  • No.of HBond Acceptors6
  • No.of Rotatable Bonds4
  • TPSA61.94
  • StatusFDA approved
  • AdministrationOral and extended-release intramuscular injection
  • PharmacologyAn atypical antipsychotic used to treat schizophrenia (including adolescent schizophrenia), the mixed and manic states associated with bipolar disorder, and irritability in children with autism.
  • Absorption_value97.0
  • Absorption (description)Well absorbed. The absolute oral bioavailability of risperidone is 70% (CV=25%). The relative oral bioavailability of risperidone from a tablet is 94% (CV=10%) when compared to a solution.
  • Caco_2N/A
  • Bioavailability66.0
  • Protein binding89.0
  • Volume of distribution (VD)1.1 L/kg (extensive metabolisers); 2.1 L/kg (intermediate); 0.7 L/kg (poor)
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmThe main metabolic pathway is through hydroxylation of risperidone to 9-hydroxyrisperidone by the enzyme, CYP 2D6. A minor metabolic pathway is through N-dealkylation. The main metabolite, 9-hydroxyrisperidone, has similar pharmacological activity as risperidone. Consequently, the clinical effect of the drug results from the combined concentrations of risperidone plus 9-hydroxyrisperidone.
  • Half life3.2 h
  • ExcretionUrinary
  • Urinary Excretion3
  • Clerance5.4 ml/min/kg
  • ToxicitySymptoms of overdose include drowsiness, sedation, tachycardia, hypotension, and extrapyramidal symptoms. LD50=82.1mg/kg (orally in mice).
  • LD50 (rat)N/A
  • LD50 (mouse)N/A